Geographic and Temporal Trends of Transmitted HIV-1 Drug Resistance Among Antiretroviral-Naïve Subjects Screening for Two Clinical Trials in North America and Western Europe

Abstract Purpose: To determine the prevalence of transmitted drug resistance (TDR) in antiretroviral (ARV)-naïve HIV-1-infected subjects who were screened for two clinical trials by geographic region and time. Methods: Studies M03-613 and M05-730 screened ARV-naïve subjects in 2004 and 2005–2006, respectively. Screening drug resistance genotype assays were performed using population sequencing, and prevalence of drug resistance mutations (DRMs) was assessed at 39 amino acid positions in HIV-1 protease and reverse transcriptase (RT) and compared between geographic regions and calendar years. Results: In 913 subjects, the prevalence of DRMs was higher in North America than in Western Europe, including any DRM (13.6% vs. 6.8%, p < .001), non-nucleoside reverse transcriptase inhibitor (NNRTI) DRMs (7.3% vs. 3.2%, p = .006), protease inhibitor (PI) DRMs (3.6% vs. 0.8%, p = .004), and nucleoside reverse transcriptase inhibitor (NRTI) DRMs (6.1% vs. 3.8%, p = ns). The prevalence of TDR to NNRTIs was higher compared to PIs within each region (p = .031 for North America, and p = .011 for Western Europe). Logistic regression analysis suggested a higher prevalence of DRMs in 2005–2006 compared to 2004 for NNRTIs (p = .03) and, to a lesser extent, for PIs (p = .07). Conclusion: TDR to NNRTIs was more frequent than to PIs in both geographic regions, increased over time, and was highest in North America.

[1]  D. Podzamczer,et al.  A Once-Daily Lopinavir/Ritonavir-Based Regimen Is Noninferior to Twice-Daily Dosing and Results in Similar Safety and Tolerability in Antiretroviral-Naive Subjects Through 48 Weeks , 2009, Journal of acquired immune deficiency syndromes.

[2]  A. V. van Loon,et al.  HIV-1 drug resistance genotyping quality assessment: results of the ENVA7 Genotyping Proficiency Programme. , 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[3]  H. Gunthard,et al.  Update of the Drug Resistance Mutations in HIV-1. , 2008, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[4]  B. Masquelier,et al.  Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy , 2008, AIDS.

[5]  M. King,et al.  A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. , 2008, The Journal of infectious diseases.

[6]  S. Hammer,et al.  The challenge of HIV-1 subtype diversity. , 2008, The New England journal of medicine.

[7]  D. Richman,et al.  Update of the drug resistance mutations in HIV-1: 2007. , 2007, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[8]  A. Geretti,et al.  Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. , 2007, The Journal of antimicrobial chemotherapy.

[9]  D. Richman,et al.  Clinical utility of HIV standard genotyping among antiretroviral-naive individuals with unknown duration of infection. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  Soo-Yon Rhee,et al.  HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance , 2007, AIDS.

[11]  Sarah Palmer,et al.  Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy , 2006, AIDS.

[12]  M. Peeters,et al.  HIV type 1 pol gene diversity and antiretroviral drug resistance mutations in the Democratic Republic of Congo (DRC). , 2006, AIDS research and human retroviruses.

[13]  D. Pillay,et al.  Evolution of Transmitted HIV-1 with Drug-Resistance Mutations in the Absence of Therapy: Effects on Cd4+ T-Cell Count and HIV-1 Rna Load , 2006, Antiviral therapy.

[14]  E. Paxinos,et al.  Genotypic and phenotypic analyses of human immunodeficiency virus type 1 in antiretroviral drug-naive Nigerian patients. , 2006, AIDS research and human retroviruses.

[15]  D. Pillay,et al.  Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study , 2005, BMJ : British Medical Journal.

[16]  Hauke Walter,et al.  Detection of minor populations of drug-resistant HIV-1 in acute seroconverters , 2005, AIDS.

[17]  Klaus Korn,et al.  Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. , 2005, The Journal of infectious diseases.

[18]  Jonathan AC Sterne,et al.  Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study , 2005, The Lancet.

[19]  V. Soriano,et al.  Antiretroviral recommendations may influence the rate of transmission of drug-resistant HIV type 1. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  H. Sørensen,et al.  Declining Prevalence of HIV-Infected Individuals at Risk of Transmitting Drug-Resistant HIV in Denmark during 1997–2004 , 2005, Antiviral therapy.

[21]  D. Richman,et al.  Confronting the emergence of drug-resistant HIV type 1: impact of antiretroviral therapy on individual and population resistance. , 2005, AIDS research and human retroviruses.

[22]  M. Zazzi,et al.  Evidence of Differential Selection of HIV-1 Variants Carrying Drug-Resistant Mutations in Seroconverters , 2005, Antiviral therapy.

[23]  J. Warren,et al.  Emerging Incidence of Enterococcus faecium among Hospital Isolates (1993 to 2002) , 2005, Journal of Clinical Microbiology.

[24]  M. Wainberg,et al.  Diminished Representation of HIV-1 Variants Containing Select Drug Resistance-Conferring Mutations in Primary HIV-1 Infection , 2004, Journal of acquired immune deficiency syndromes.

[25]  Deenan Pillay,et al.  Current Patterns in the Epidemiology of Primary HIV Drug Resistance in North America and Europe , 2004, Antiviral therapy.

[26]  J. Weber,et al.  Performance of two commercially available sequence‐based HIV‐1 genotyping systems for the detection of drug resistance against HIV type 1 group M subtypes , 2003, Journal of medical virology.

[27]  Simon D W Frost,et al.  Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. , 2003, The Journal of infectious diseases.

[28]  G. d’Ettorre,et al.  Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy , 2003, Journal of medical virology.

[29]  Elizabeth Connick,et al.  Antiretroviral-drug resistance among patients recently infected with HIV. , 2002, The New England journal of medicine.

[30]  J. Kahn,et al.  Time trends in primary HIV-1 drug resistance among recently infected persons. , 2002, JAMA.

[31]  Diana D. Huang,et al.  Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. , 2002, AIDS research and human retroviruses.

[32]  Robert Shafer,et al.  HIV-1 Genotypic Resistance Patterns Predict Response to saquinavirritonavir Therapy in Patients in Whom Previous Protease Inhibitor Therapy Had Failed , 1999, Annals of Internal Medicine.

[33]  C. Boucher,et al.  Worldwide Evaluation of DNA Sequencing Approaches for Identification of Drug Resistance Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase , 1999, Journal of Clinical Microbiology.

[34]  P. Volberding,et al.  Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. , 1999, The Journal of infectious diseases.

[35]  R. Hogg,et al.  Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[36]  J. J. Henning,et al.  Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.

[37]  D. Cooper,et al.  Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group. , 1997, The Journal of infectious diseases.

[38]  H. Schuitemaker,et al.  Transmission of zidovudine-resistant human immunodeficiency virus type 1 variants following deliberate injection of blood from a patient with AIDS: characteristics and natural history of the virus. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.